Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia
Authors: Sharma Shringi , Guo Ying , Jin Feng , Li Xiaoming , Dubowy Ronald L. , Newcomb Terry , Ramanathan Srini 
Published: October 2019

Abstract
Background:
Idelalisib (Zydelig®) is a potent and selective PI3Kδ inhibitor approved for the treatment of relapsed CLL (in combination with rituximab) and relapsed iNHL subtypes, FL and SLL. Relationship between plasma exposures to idelalisib or its inactive circulating metabolite, GS-563117, and clinical efficacy and safety were evaluated in relapsed/refractory CLL subjects following administration of idelalisib 150 mg twice daily (BID) in combination with ofatumumab (Study GS-US-312-0119).
Methods:
Idelalisib and GS-563117 plasma exposures (Cmax, AUCtau and Ctau) were generated using population pharmacokinetic models based on data from several phase 1/2/3 clinical studies. Efficacy and safety data from the Phase 3, randomized, open-label study (GS-US-312-0119) were included in the PK/PD analyses.
Efficacy endpoints including best overall response rate (BOR), duration of response (DOR), progression -free survival (PFS), sum of products of the greatest perpendicular diameters (SPD) of index lesions, and lymph node response rate (LNR) were evaluated against idelalisib plasma exposure (AUCtau and Ctau). Safety endpoints evaluated included ≥ Grade 3 neutropenia, skin rash, infection, pneumonia, pneumonitis, diarrhea, colitis, and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation versus idelalisib and GS-563117 plasma exposure (AUCtau and Cmax). Kaplan-Meier survival analysis, Cox proportional hazard model/Logistic regression analyses were conducted for key efficacy and safety endpoints.
Results:
Median idelalisib exposures were similar between responders (complete response [CR] or partial response [PR]) versus nonresponders (stable disease [SD] or progressive disease [PD]) and across the 4 response categories (p≥0.67; Table 1). As idelalisib exposure increased over quartiles, there was no clear trend of prolonged DOR (p≥0.49), PFS (p≥0.15) or change in SPD. No relationship between LNR (responder versus non-responder) and idelalisib exposures was observed.
No association was observed between idelalisib or GS-563117 plasma exposure vs incidence of neutropenia, diarrhea (p≥0.50), skin rash, infection (p≥0.18), pneumonia (p≥0.38), pneumonitis (p≥0.20), colitis (p≥0.43), and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation.
Conclusions:
No exposure-response relationships were observed for efficacy or safety endpoints at idelalisib 150 mg BID. These results are consistent with previous findings of exposure to idelalisib in subjects with CLL (in combination with rituximab) and iNHL and support idelalisib 150 mg BID in combination with ofatumumab for the treatment of CLL.
Table 1. Summary of idelalisib Ctau in Study GS-US-312-0119 based on BOR category/status BOR Category BOR Status Responder Non-responder CR PR SD PD N 131 40 1 130 30 1 Median (ng/mL) 353 377 298 353 338 583 Q1, Q3 (ng/mL) 229, 518 268, 504 298, 298 229, 518 233, 433 583, 583 Min, Max (ng/mL) 76.2, 1529 62, 1184 298, 298 76.2, 1529 62, 1184 583, 583 CR: complete responder, PR: partial responder, SD: stable disease, PD: progressive disease. CR and PR were responder; SD and PD were non-responder.

Disclosures
Sharma: Gilead Sciences: Employment, Equity Ownership. Guo:Gilead Sciences: Employment, Equity Ownership. Jin:Gilead Sciences: Employment, Equity Ownership. Li:Gilead Sciences: Employment, Equity Ownership. Dubowy:Gilead Sciences: Employment, Equity Ownership. Newcomb:Gilead: Employment. Ramanathan:Gilead Sciences: Employment, Equity Ownership.